Cambridge Epigenetix Closes $21M Series B Financing
News Mar 15, 2016
Cambridge Epigenetix has announced the close of a $21 million Series B financing and the appointment of Dr. Geoff Smith as CEO. The round was led by GV (formerly Google Ventures), with significant participation from Sequoia Capital. Current investors New Science Ventures, Syncona Partners and Cambridge University also joined the round. In conjunction with the fundraising, Tom Hulme, GV general partner, will join CEGX’s board of directors and co-founder Dr. Bobby Yerramilli-Rao will assume the role of Chairman.
New CEO Dr. Geoff Smith joins CEGX from Illumina, where he served most recently as site lead and VP of Product Development. “CEGX is today ideally positioned to catalyze the market for epigenetics – just as Solexa and Illumina did for genomics a decade ago – and I am thrilled to have joined at such a transformational time for the company and in driving the next generation of epigenetics products” added Dr. Smith, concluding, “We appreciate the continued support of our existing investors, and look forward to working with our new investors, whose unparalleled expertise in building data-driven businesses of substantial value will be key.”
“CEGX’s mission is to promote better health through continuous measurement of the epigenome.” said Dr. Yerramilli-Rao. “CEGX’s novel technologies are allowing scientists to begin unlocking the tremendous potential of epigenetics. Geoff’s decades of experience in the genomics and Next-Generation Sequencing (NGS) industries position him uniquely to lead CEGX. We are thrilled to have him on board.”
Prof. Shankar Balasubramanian, co-founder of CEGX previously co-founded Solexa to develop Sequencing by Synthesis which is now the basis for Illumina’s market-leading NGS technology. CEGX was founded on similarly cutting-edge, patented technology which is now in use in labs around the world and continues to form the technological backbone for breakthrough work in epigenetics.
GV’s Tom Hulme said "We’ve seen how the commercialization of genome sequencing has created incredible opportunities to improve human health, and now the epigenome holds similar potential. Cambridge Epigenetix is one of the few teams on the planet with the skills and experience to break new ground here, and we look forward to supporting them on that journey.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.